PET brain scans show many Alzheimer’s patients may not actually have the disease

Posted on July 19, 2017 in Health Debates – News/World – A major four-year study of more than 18,000 dementia patients reveals that a large number do not have amyloid plaques in their brains, one of the hallmarks of Alzheimer’s. “We see high percentages of people who are on a drug and didn’t need to be on those drugs,” said one researcher.
July 19, 2017.   By TARA BAHRAMPOUR, The Washington Post

A significant portion of people with mild cognitive impairment or dementia who are taking medication for Alzheimer’s may not actually have the disease, according to interim results of a major study currently underway to see how PET scans could change the nature of Alzheimer’s diagnosis and treatment.

The findings, presented Wednesday at the Alzheimer’s Association International Conference in London, come from a four-year study launched in 2016 that is testing more than 18,000 Americans with MCI or dementia to see if their brains contain the amyloid plaques that are one of the two hallmarks of the disease.

So far, the results have been dramatic. Among 4,000 people tested so far in the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) study, researchers from the Memory and Aging Center at the University of California, San Francisco found that just 54.3 per cent of MCI patients and 70.5 per cent of dementia patients had the plaques.

A positive test for amyloid does not mean someone has Alzheimer’s, though its presence precedes the disease and increases the risk of progression. But a negative test definitively means a person does not have it.

The findings could change the way doctors treat people in these hard-to-diagnose groups and save money currently being spent on inappropriate medication.

“To get that right diagnosis, that’s really important,” said Cynthia Guzman of Napa, California, whose initial Alzheimer’s diagnosis was ruled out in an earlier PET scan study.

Guzman had unusual fluctuating memory problems. Some days she functioned normally. Others, she’d stop her car at a stop sign without knowing how she got there or where she was going. Eventually, tremors and hallucinations led specialists to conclude she has Lewy body dementia. Knowing, Guzman said, has allowed her to avoid a list of common medications that could worsen her symptoms.

“If someone had a putative diagnosis of Alzheimer’s disease, they might be on an Alzheimer’s drug like Aricept or Namenda,” said James Hendrix, the Alzheimer Association’s director of global science initiatives who co-presented the findings. “What if they had a PET scan and it showed that they didn’t have amyloid in their brain? Their physician would take them off that drug and look for something else.”

For decades, diagnosing Alzheimer’s has been a guessing game, based on looking at a person’s symptoms rather than testing for definitive evidence of the brain disorder. A firm diagnosis was not possible until an autopsy was performed.

Now, a spinal tap or PET scan can detect the telltale amyloid deposits, and researchers are trying to develop a simple blood test that would do so. PET imaging can quantify the amount of amyloid and also show where it is in a person’s brain.

But spinal taps are invasive, and PET scans cost $3,000 to $4,000 (U.S.) and are typically not covered by insurance. In 2013 the Centers for Medicare & Medicaid Services (CMS) declined to cover the tests, citing insufficient evidence that they would make a difference for patients with a disease for which there is no cure and limited treatment available.

But CMS agreed to fund the bulk of the $100 million IDEAS study by reimbursing participants for their PET scans, and researchers hope positive results will convince them to cover it in the future.

Over 400 physicians enrolled their patients in the study, and they initially filled out forms describing how they would care for them based on their clinical symptoms. After seeing the PET imaging results, they changed their care plans for two-thirds of the patients in the study.

“We thought we would be able to see about a 30 per cent change, but we’re getting a 66 per cent change, so it’s huge,” Hendrix said. “We see high percentages of people who are on a drug and didn’t need to be on those drugs.”

Also on Wednesday, the Alzheimer’s Association announced the launch of a $20 million two-year clinical trial to see if lifestyle changes can prevent cognitive decline.

Modelled after a larger 2014 study in Finland that showed positive results, The US POINTER study will work with 2,500 older adults at risk for cognitive decline. It will test whether two years of intervention that includes physical exercise, nutritional counselling, social and cognitive stimulation, and improved self-management will help cognitive function in participants 60 to 79 years old.

Similar studies are also underway in Singapore and Australia.

Research has shown that each of these factors contributes to cognitive health, but researchers believe that, as with heart disease, combating Alzheimer’s is likely to require a multi-pronged, or “cocktail” approach combining drugs and lifestyle changes.

“We all hope for a day when this will be critically important,” said Dr. Richard Hodes, director of the National Institute on Aging, who wasn’t involved with the IDEAS study.

For now, in addition to people who qualify for the IDEAS study, the Alzheimer’s Association and Society of Nuclear Medicine and Molecular Imaging say:

— Unusually young dementia patients, younger than 65, also might be candidates for a PET scan.

— The scans shouldn’t be used as a screening tool for people without symptoms or who worry they’re at risk.

— Nor are they for people who can be diagnosed by standard means, or to determine disease severity.

Tags: , , , , ,

This entry was posted on Wednesday, July 19th, 2017 at 3:00 pm and is filed under Health Debates. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.

Leave a Reply